Oncology Business Management | Specialty

FDA Approves Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer

November 5th 2014

The FDA has approved the combination of ramucirumab and paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

CMS Finalizes 2015 Payment Schedule

November 4th 2014

This past Friday, the Centers for Medicare and Medicaid Services (CMS) released nearly 3,000 pages of regulations finalizing 2015 payment rates for various providers and services in the Medicare program, including physicians.

Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes

October 30th 2014

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

Financial Burden of Cancer Treatment Weighs Heavily on Patients

October 28th 2014

Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.

ICD-10 and Urologic Oncology: A Disappointing Combination

October 24th 2014

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).

As Hospitals Acquire Medical Practices, Cost of Patient Care Goes Up

October 24th 2014

Even as more hospitals seek to acquire medical groups and physician practices, this consolidation leads to higher expenditures through greater use of hospital-based ambulatory services, according to a recent study from the University of California, Berkeley School of Public Health.

Big Promise From Big Data

October 24th 2014

How can we slow down the growth of cancer costs and preserve-or better yet-enhance clinical outcomes?

Z-Code Identifiers Give Providers Objective Information About Molecular Tests

October 23rd 2014

Virtually everyone in the clinical laboratory business is now acquainted with Z-code identifiers. Each unique laboratory test should have a unique tracking code, even if more than one Z-code identifier is reported with a corresponding American Medical Association's Current Procedural Terminology (CPT) billing code.

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

The Promise of Big Data Gets Closer to Fulfillment

October 21st 2014

It seems like big data is everywhere these days. It's being touted as a solution for physicians and practices who would like to participate in Accountable Care Organizations (ACOs) and accountable care-like contracts with payers.

City of Hope Joins OncLive's Strategic Alliance Partnership Program

October 17th 2014

City of Hope teams with OncLive to further promote its distinctions and innovations in cancer care. As a member of OncLive's Strategic Partnership program, City of Hope will have the opportunity to promote its state-of-the-art comprehensive cancer center and the center's latest scientific discoveries, treatment and prevention strategies.

Americans Enrolled in High-Deductible Health Plans Concerned About Medical Expenses

October 15th 2014

Most privately insured Americans between the ages of 18 and 64 are satisfied with their health care plans, but for those enrolled in high-deductible health plans (HDHPs), a different story emerges.

FDA Grants Priority Review to Blinatumomab in Adult ALL

October 9th 2014

The FDA has assigned a priority review designation to blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

FDA Schedules ODAC Hearing for Panobinostat in Multiple Myeloma

October 9th 2014

The FDA has scheduled an ODAC advisory hearing to discuss the new drug application for panobinostat in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Olaparib in Ovarian Cancer

October 9th 2014

Maurie Markman on Patient-Centered Cancer Care

October 9th 2014

Herbert Irving Comprehensive Cancer Center

October 9th 2014

Latest News & Insight: October 9, 2014

October 9th 2014

2014 ESMO Congress Highlights

October 9th 2014

Revenue Cycle Management in a Post-ACA World

October 7th 2014

The Affordable Care Act (ACA) is bringing unprecedented changes to how health care is paid for in the US, and both primary care physicians and specialists need to understand how these changes will affect their revenues.